Talazoparib + Irinotecan + Temozolomide + Filgrastim + Peg-filgrastim
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Solid Tumors
Conditions
Childhood Solid Tumors
Trial Timeline
Mar 25, 2015 → Aug 30, 2019
NCT ID
NCT02392793About Talazoparib + Irinotecan + Temozolomide + Filgrastim + Peg-filgrastim
Talazoparib + Irinotecan + Temozolomide + Filgrastim + Peg-filgrastim is a phase 1 stage product being developed by Pfizer for Childhood Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02392793. Target conditions include Childhood Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02392793 | Phase 1 | Completed |
Competing Products
20 competing products in Childhood Solid Tumors